These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17286539)

  • 1. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.
    Arbouw ME; van Vugt JP; Egberts TC; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):159-76. PubMed ID: 17286539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacogenetics in Parkinson's disease treatment].
    Białecka M; Kłodowska-Duda G; Kurzawski M; Droździk M
    Neurol Neurochir Pol; 2008; 42(2):131-8. PubMed ID: 18512170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic considerations in the treatment of Parkinson's disease.
    Kurzawski M; Białecka M; Droździk M
    Neurodegener Dis Manag; 2015; 5(1):27-35. PubMed ID: 25711452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
    Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S
    Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease pharmacogenomics: new findings and perspectives.
    Schumacher-Schuh AF; Rieder CR; Hutz MH
    Pharmacogenomics; 2014 Jun; 15(9):1253-71. PubMed ID: 25141900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insights in pharmacogenetics of drug response in Parkinson's disease.
    Arbouw ME; Guchelaar HJ; Egberts TC
    Pharmacogenomics; 2010 Feb; 11(2):127-9. PubMed ID: 20136351
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenetics of drug response in Parkinson's disease.
    Džoljić E; Novaković I; Krajinovic M; Grbatinić I; Kostić V
    Int J Neurosci; 2015; 125(9):635-44. PubMed ID: 25226559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.
    Jiménez-Jiménez FJ; Alonso-Navarro H; García-Martín E; Agúndez JA
    Expert Opin Drug Metab Toxicol; 2016; 12(4):433-48. PubMed ID: 26910127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
    Liu JS; Chen Y; Shi DD; Zhang BR; Pu JL
    Curr Neuropharmacol; 2023; 21(3):536-546. PubMed ID: 36582064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson's disease.
    Ayuso P; Jiménez-Jiménez FJ; Gómez-Tabales J; Alonso-Navarro H; García-Martín E; Agúndez JAG
    Expert Opin Drug Metab Toxicol; 2023; 19(7):447-460. PubMed ID: 37599424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.
    Skipper L; Liu JJ; Tan EK
    Expert Opin Pharmacother; 2006 May; 7(7):849-55. PubMed ID: 16634708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
    Damasceno Dos Santos EU; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
    J Clin Pharmacol; 2019 Jul; 59(7):1006-1013. PubMed ID: 30794329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.
    Vautier S; Fernandez C
    Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1349-58. PubMed ID: 19663741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying poor symptom control in Parkinson's disease.
    Scott L
    Nurs Times; 2006 Mar 21-27; 102(12):30-2. PubMed ID: 16594560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics of Alzheimer's and Parkinson's diseases.
    Cacabelos R
    Neurosci Lett; 2020 May; 726():133807. PubMed ID: 30236877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug therapy in the management of Parkinson's disease.
    Stevenson T
    Br J Nurs; 1997 Feb 13-26; 6(3):144-8, 150. PubMed ID: 9104119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Payami H
    Mov Disord; 2017 Aug; 32(8):1139-1146. PubMed ID: 28686320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
    Masellis M; Collinson S; Freeman N; Tampakeras M; Levy J; Tchelet A; Eyal E; Berkovich E; Eliaz RE; Abler V; Grossman I; Fitzer-Attas C; Tiwari A; Hayden MR; Kennedy JL; Lang AE; Knight J;
    Brain; 2016 Jul; 139(Pt 7):2050-62. PubMed ID: 27190009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
    Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
    CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs of abuse and Parkinson's disease.
    Mursaleen LR; Stamford JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():209-17. PubMed ID: 25816790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.